ES2396613T3 - Imidazopirazinas e imidazotriazinas sustituidas - Google Patents

Imidazopirazinas e imidazotriazinas sustituidas Download PDF

Info

Publication number
ES2396613T3
ES2396613T3 ES09751280T ES09751280T ES2396613T3 ES 2396613 T3 ES2396613 T3 ES 2396613T3 ES 09751280 T ES09751280 T ES 09751280T ES 09751280 T ES09751280 T ES 09751280T ES 2396613 T3 ES2396613 T3 ES 2396613T3
Authority
ES
Spain
Prior art keywords
alkyl
independently selected
substituted
cr8r9
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09751280T
Other languages
English (en)
Inventor
Andrew P. Crew
Meizhong Jin
Mridula Kadalbajoo
Andrew Kleinberg
Mark J. Mulvihill
Jing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2396613T3 publication Critical patent/ES2396613T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un compuesto de acuerdo con la Fórmula I: en la que: A es CH o N; Q1 es -X1-Y1-Z1; o Q1 es: X1 es cíclico5-10, que puede estar sustituido con uno o más grupos G1 seleccionados independientemente; Y1 se selecciona entre >C(R2)R3, >C(OR2)R3, >C>=O, >C>=C(R2)R3, >C>=NR2, >C>=NOR2, >NR2, >O, >S(O)m; Z1 se selecciona entre cíclico5-10 o alcoxi C1-6, cualquiera de los cuales puede estar sustituido con uno o más gruposG1 seleccionados independientemente; y en la que cuando Y es >O y R1 es ciclobutilo, al menos uno de X o Z está sustituido; cada caso de G1 seselecciona independientemente entre halo, -CN, -CF3, -OCF3, -NO2, alquilo C1-6, cíclico3-6alquilo C0-6, -OR4, -NR4R5, -C(O)R4, -C(O)NR4R5, -C(O)OR4 o -NR4C(O)R5 , cualquiera de los cuales puede estar sustituido con uno o más grupos G2 seleccionados independientemente; cada caso de G2 se selecciona independientemente entre halo, -CN, -OH, -NH2, -NO2, oxo, -CF3, -OCF3 o alquilo C1-6, cualquiera de los cuales puede estar sustituido con uno o más grupos seleccionados independientemente entrehalo, -CN, -OH, -NH2, alquilo C1-6 (en el que cualquiera de los siguientes puede estar parcial o totalmentehalogenado), -Oalquilo C1-6 o -N(alquil C1-6) alquilo C1-6; cada caso de G3 se selecciona independientemente entre halo, oxo, -CN, -CF3, -OCF3, alquilo C1-6, cíclico3-6alquiloC0-6, -OR8, -NR8R9, -C(O)R8, -C(O)NR8R9, -C(O)OR8, -NR8C(O)R9, -(CR8R9)nNR6R7, -(CR8R9)nOR6, -NR8C(O)OR9, -O(CR8R9)nNR6R7, -N(CR8R9)nOR6 o - (CR8R9)nNR6C(O)OR7, cualquiera de los cuales puede estar sustituido con unoo más sustituyentes G2 seleccionados independientemente R1 se selecciona entre -SR2, alquilo C1-6, 5,6-bicíclicoarilo, o cíclico3-6, cualquiera de los cuales puede estar sustituidocon uno o más grupos G3 seleccionados independientemente; cada caso de R2 y R3 se selecciona independientemente entre H, halo o -alquilo C1-6; cada caso de R4, R5, R6, R7, R8, R9 se selecciona independientemente entre H, alquilo C1-6 o cíclico3-6alquilo C0-6; enlos que cualquier par R4/R5, R6/R7, R8/R9, junto con el átomo al que está unido, puede formar un cíclico3-6 quepueden incluir uno o más heteroátomos seleccionados entre O, N(alquilo C0-3) o S(O)m; cada m se selecciona independientemente entre 0-2; y cada n se selecciona independientemente entre 0-4; o una sal farmacéuticamente aceptable del mismo.
ES09751280T 2008-05-19 2009-05-18 Imidazopirazinas e imidazotriazinas sustituidas Active ES2396613T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5434508P 2008-05-19 2008-05-19
US54345P 2008-05-19
PCT/US2009/044325 WO2009143051A1 (en) 2008-05-19 2009-05-18 Substituted imidazopyr-and imidazotri-azines

Publications (1)

Publication Number Publication Date
ES2396613T3 true ES2396613T3 (es) 2013-02-22

Family

ID=40983400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09751280T Active ES2396613T3 (es) 2008-05-19 2009-05-18 Imidazopirazinas e imidazotriazinas sustituidas

Country Status (5)

Country Link
US (1) US8481733B2 (es)
EP (1) EP2283020B8 (es)
JP (1) JP2011520970A (es)
ES (1) ES2396613T3 (es)
WO (1) WO2009143051A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230818B2 (en) 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
AU2012221828C1 (en) 2011-02-23 2015-10-01 Pfizer Inc. Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
HUE027461T2 (en) 2011-07-13 2016-09-28 Basf Agro Bv Fungicide substituted 2- [2-haloalkyl-4- (phenoxyphenyl) -1- [1,2,4] triazol-1-yl-ethanol compounds
IN2014CN00832A (es) 2011-07-15 2015-04-03 Basf Se
CN103648281B (zh) 2011-07-15 2016-05-25 巴斯夫欧洲公司 杀真菌的烷基取代的2-[2-氯-4-(4-氯苯氧基)苯基]-1-[1,2,4]***-1-基乙醇化合物
UY34258A (es) 2011-08-15 2013-02-28 Basf Se Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos
MX2014000824A (es) 2011-08-15 2014-02-27 Basf Se Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos.
JP2014529594A (ja) 2011-08-15 2014-11-13 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性置換１−｛２−シクリルオキシ−２−［２−ハロ−４−（４−ハロゲン−フェノキシ）−フェニル］−エチル｝−１ｈ−［１，２，４］トリアゾール化合物
CN103374001B (zh) * 2012-04-19 2015-10-28 山东轩竹医药科技有限公司 咪唑并三嗪类mTOR抑制剂
KR20150061651A (ko) * 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
PL2934147T3 (pl) 2012-12-20 2020-06-29 BASF Agro B.V. Kompozycje zawierające związki triazolowe
PL3219707T3 (pl) 2013-01-09 2020-01-31 BASF Agro B.V. Sposób wytwarzania podstawionych oksiranów i triazoli
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
RU2669997C2 (ru) 2013-07-08 2018-10-17 Басф Агро Б.В. Композиции, содержащие триазольное соединение и биопестицид
US20210317140A1 (en) * 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
CA2833867A1 (en) 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
EA032078B1 (ru) 2014-06-25 2019-04-30 Басф Агро Б.В. Пестицидные композиции
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
BR112017009282A2 (pt) 2014-11-07 2018-01-30 Basf Se misturas fungicidas, composição pesticida, métodos para controlar pragas fitopatogênicas, para melhorar a fitossanidade e para proteção de material de propagação de plantas contra pragas, e, material de propagação de plantas.
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
KR102416971B1 (ko) * 2016-03-11 2022-07-04 엔젤 파마슈티칼 컴퍼니, 리미티드 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
US10905122B2 (en) 2016-03-16 2021-02-02 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals
BR112018068695B1 (pt) 2016-03-16 2022-12-27 Basf Se Uso de um composto e método para controlar fungos fitopatogênicos
CN106831787B (zh) * 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
AU2018237123B2 (en) 2017-03-22 2022-08-04 Xibin Liao Bruton's tyrosine kinase inhibitors
MX2020002322A (es) * 2017-09-01 2020-10-05 Optikira Llc Compuestos y composiciones para la inhibicion de ire1.
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
AU2020207953A1 (en) * 2019-01-18 2021-08-26 Hangzhou Bangshun Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
ES2961673T3 (es) * 2019-03-15 2024-03-13 Alterity Therapeutics Ltd Compuestos para y métodos para tratar enfermedades
US20230122807A1 (en) * 2020-01-02 2023-04-20 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Btk inhibitors
US11155547B1 (en) 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
MX9304801A (es) 1992-08-06 1997-06-28 Warner Lambert Co 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales.
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
HUP0201480A3 (en) 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
BR0013219A (pt) 1999-08-12 2002-04-23 American Cyanamid Co Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
SK12002003A3 (en) 2001-03-28 2004-10-05 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
RU2003134180A (ru) 2001-05-08 2005-02-10 Мерк Патент ГмбХ (DE) Комбинированная терапия, использующая антитела к egfr и антигормональные средства
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
GB0122560D0 (en) 2001-09-19 2001-11-07 Aventis Pharma Ltd Chemical compounds
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
CA2470088A1 (en) 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
US20050215564A1 (en) 2002-02-14 2005-09-29 Stiles Charles D Methods and compositions for treating hyperproliferative conditions
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
JP2005530735A (ja) 2002-04-16 2005-10-13 アストラゼネカ アクチボラグ 癌の処置のための併用療法
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
RS20050692A (en) 2003-03-12 2007-11-15 Pfizer Production Inc., Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
SG132683A1 (en) * 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005230818B2 (en) * 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
EP1768982A2 (en) * 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
DE202005016343U1 (de) 2005-10-19 2007-02-22 Weidmüller Interface GmbH & Co. KG Elektrische Steckverbindung mit Schnellentriegelung
AU2006316605B2 (en) * 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
TW200900070A (en) 2007-02-27 2009-01-01 Osi Pharm Inc Combination cancer therapy

Also Published As

Publication number Publication date
WO2009143051A1 (en) 2009-11-26
US8481733B2 (en) 2013-07-09
US20090286768A1 (en) 2009-11-19
EP2283020A1 (en) 2011-02-16
EP2283020B8 (en) 2012-12-12
JP2011520970A (ja) 2011-07-21
EP2283020B1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
ES2396613T3 (es) Imidazopirazinas e imidazotriazinas sustituidas
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR031305A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PE20160670A1 (es) PIRROLO[1,2-f][1,2,4]TRIAZINAS UTILES PARA TRATAR INFECCIONES POR EL VIRUS SINCITIAL RESPIRATORIO
AR071112A1 (es) Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.
MX2010013768A (es) Fosfatos ciclicos de nucleosidos.
GB201201744D0 (en) Novel compounds
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR073450A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
CO6190512A2 (es) Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
AR067271A1 (es) Derivados de triazolona inhibidores no nucleosidos de la transcriptasa inversa, utiles para el tratamiento de enfermedades mediadas por el vih o el arc y composiciones farmaceuticas que los contienen.
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
PE20161443A1 (es) Compuestos
AR076236A1 (es) Compuestos organicos y sus usos
ES2529691T3 (es) Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT
AR087017A1 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
AR076235A1 (es) Compuestos organicos y sus usos